Article Sidebar
Published:
Mar 18, 2019Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Combination of thymosin α1 with conventional therapy improves APC and IL-1R1 levels in children with severe pneumonia
Abstract
Purpose: To investigate the effect of a combination of thymosin α1 with conventional regimen on APC and IL-1R1 levels in children with severe pneumonia, and to provide a reference for its clinical treatment.
Methods: A total of 96 children with severe pneumonia over a period of two years were divided into control and observation groups (48 cases per group) by random number table method. The patients consisted of 46 males and 50 females within the age range of 0.1 - 6 years (mean age = 3.0 ± 1.2 years), and mean duration of 13.4 ± 2.2 days). Their acute physiology and chronic health evaluation II (APACHE II) was 20.3 ± 3.2 points. Patients in the control group were placed on conventional treatment programs, while those in the observation group, in addition to the conventional treatments, received thymosin α1 (subcutaneous injection of thymosin α1 at a dose of 1.5 mg per injection) twice daily for the first 3 days, then once daily until the 7th day, after which the adverse reactions were observed and treated. Pulmonary function indices, and levels of APC, and IL-1R1 were also determined in the patients’ sera before and after the treatment regime.
Results: The clinical efficacy of the observation group was significantly better (p < 0.05) than that of control. There were no significant differences (p > 0.05) in the indices of pulmonary function (maximal inspiratory and expiratory pressure, and peak expiratory flow) between the two groups before treatment. However, after treatment they were significantly higher (p < 0.05) in the observation group than in control. There were no significant differences (p > 0.05) in APC and IL-1R1 levels between the two groups before treatment, but after treatment, while the level of APC in the observation group was significantly increased (p < 0.05), the IL-1R1 level was significantly decreased (p < 0.05), when compared to the control group. Both groups showed no obvious adverse reactions during the treatment
regime.
Conclusion: Combining thymosin α1 with routine treatment in the management of children with severe pneumonia can significantly alleviate the symptoms of patients, greatly stimulate recovery of pulmonary function, improve APC and IL-1R1 levels, and prevent inflammation.
Keywords: Pneumonia, Thymosin α1, Routine treatment, Inflammatory factors, Pulmonary function
